Table 2. Correlation between expression of COX-2 and PPARγ and clinicopathological factors in ovarian carcinoma.
| Factor | No. of cases | Case no. (%) of COX-2 positive | Case no. (%) of PPARγ positive |
|---|---|---|---|
| Stage | |||
| I/II | 47 | 20 (42.6) | 21 (44.7) |
| III/IV | 24 | 8 (33.3) | 9 (37.5) |
| Histological type | |||
| Serous | 30 | 14 (46.7) | 10 (33.3) |
| Mucinous | 11 | 3 (27.3) | 6 (54.5) |
| Endometrioid | 17 | 6 (353) | 10 (58.8) |
| Clear cell | 12 | 5 (41.7) | 4 (33.3) |
| Undifferentiated | 1 | 0 | 0 |
| Lymph node metastasis | |||
| Positive | 10 | 6 (60.0) | 4 (40.0) |
| Negative | 61 | 22 (36.1) | 26 (42.6) |
| Outcome | |||
| Recurrent | 19 | 6 (41.6) | 8 (42.1) |
| Nonrecurrent | 52 | 22 (42.3) | 22 (42.3) |
COX-2 and PPARγ positivity in carcinomas was not correlated with clinical factors such as stage, histological type, lymph node metastasis and recurrence.